Surgical treatment of uterine sarcoma is the main method of treatment. Although prospective study has not yet sure adjuvant chemotherapy and radiotherapy, but due to uterine sarcoma high rate of recurrence (stage 5-year survival rate 50%, other phases only 0% to 20%), most scholars still advocate for adjuvant chemotherapy or radiotherapy. Collaboration Gynecologic Oncology Group (GOG) non-randomized study, in the uterus of MMMTs Ⅰ, Ⅱ patients with pelvic radiotherapy, radiotherapy can significantly reduce the recurrence, but the survival rate did not change significantly. Another non-randomized study results showed that mixed mullerian duct cancer in vitro after irradiation plus intracavitary irradiation can improve survival in patients with lower local failure rate. Radiotherapy for endometrial stromal sarcoma effective, Peters, a non-randomized controlled study results showed that doxorubicin and cisplatin combination chemotherapy effective program. GOG Phase II clinical trial results showed that uterine sarcoma Ⅲ chemotherapy with ifosfamide efficient: uterine sarcoma mesodermal to 32.2%, endometrial stromal sarcoma 33%, 17.2% of leiomyosarcoma. GOG randomized controlled study of ifosfamide, or plus cisplatin regimen can be used in the treatment of mixed mesodermal tumor recurrence in patients with advanced and the first line of chemotherapy drugs. High-dose progesterone cell differentiation good for uterine stromal sarcoma have some therapeutic effect.
Tags:
cell,
endometrial,
patient,
patients,
radiation,
radiotherapy,
recurrence,
treatment